Long-Term Remissions of Patients With Follicular Lymphoma Grade 3 Treated With R-CHOP

Conclusion R-CHOP is an effective first-line treatment for patients with FLG3, and might provide extended PFS, comparable with outcomes observed in diffuse large B-cell lymphoma, particularly in subgroups with limited nodal disease. Micro-Abstract The optimal management of patients with follicular lymphoma grade 3 (FLG3) is controversial. We analyzed 45 patients with FLG3 treated with first-line rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). R-CHOP showed to be an effective first-line treatment for these patients, and provided extended PFS, comparable with outcomes observed in diffuse large B-cell lymphoma, particularly in subgroups with limited nodal disease.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research